Cimzia's value in patients with psoriasis demonstrated

New data supporting the long-term safety of Cimzia (certolizumab pegol), the only Fc-free, PEGylated anti-tumor necrosis factor (TNF), in patients with moderate-to-severe plaque psoriasis, and new efficacy data for patients who show signs of psoriasis-related nail disease and those who had an inadequate early treatment response to Cimzia, were released today by UCB (Euronext Brussels: UCB), Belgium’s largest drugmaker, whose share were up 1.2% at 71.00 euros.

These findings are being presented at the 6th Congress of the Skin Inflammation & Psoriasis International Network (SPIN), in Paris, April 25-27, 2019. Cimzia is already one of UCB’s top selling products, generated revenues of 1.4 billion euros ($1.57 billion) in 2018.

“This new research demonstrates UCB’s ongoing commitment to delivering meaningful outcomes for psoriasis patients, where there is still significant unmet need. This includes patients with psoriatic nail disease and those who do not initially adequately respond to their treatment dose. The multitude of evidence from these ongoing trials complements data from across all areas of chronic inflammatory diseases to show the value of Cimzia in treating different patient populations,” said Emmanuel Caeymaex, head of immunology and executive vice president at UCB.